Alzheimer Disease Clinical Trials in Orlando, Florida

8 studies are recruiting for alzheimer disease in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

   The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who c…

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 1635, Orlando, Florida

   Locations

   252 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06937229 on ClinicalTrials.gov

2. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Combined Research Orlando (CRO), Orlando, Florida

   Locations

   162 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011732 on ClinicalTrials.gov

3. Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

   This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P…

   Stage

   Phase 2

   Ages

   55 to 80

   Site

   Conquest Research - Lake Nona, Orlando, Florida

   Locations

   38 in total

   Run by

   Lighthouse Pharmaceuticals, Inc.

   See if you can join NCT06847321 on ClinicalTrials.gov

4. A Study of LY3439539 in Participants With Alzheimer's Disease

   The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month.

   Stage

   Phase 1

   Ages

   50 to 85

   Site

   Charter Research, Orlando, Florida

   Locations

   11 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07598370 on ClinicalTrials.gov

5. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

   This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

   Stage

   Phase 2

   Ages

   55 and older

   Site

   Combined Research Orlando, Orlando, Florida

   Locations

   67 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06540833 on ClinicalTrials.gov

6. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Charter Research Orlando, Orlando, Florida

   Locations

   293 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

7. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Charter Research - Orlando, Orlando, Florida

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

8. ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

   The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

   Stage

   Not phased

   Ages

   50 to 85

   Site

   Advent Health, Orlando, Florida

   Locations

   10 in total

   Run by

   InSightec

   See if you can join NCT03671889 on ClinicalTrials.gov